Welcome to our dedicated page for Therapeuticsmd news (Ticker: TXMD), a resource for investors and traders seeking the latest updates and insights on Therapeuticsmd stock.
TherapeuticsMD, Inc. (NASDAQ: TXMD) is described in its public communications as a company that owns rights to pharmaceutical royalties and operates as a pharmaceutical royalty company. Its recurring news releases focus on financial results and business updates related to this royalty-based model. Each quarter, the company issues press releases detailing net income or net loss from continuing operations, license revenues primarily associated with the Mayne License Agreement, and total operating expenses from continuing operations.
These earnings announcements highlight how changes in sales of licensed products by TherapeuticsMD’s licensees affect license revenue, and how the company’s transition from a commercializing pharmaceutical business to a royalty-based business has influenced its cost structure. The company frequently discusses reductions in operating expenses, including lower general and administrative costs, and refers to efficiencies realized as a royalty-based business with more limited infrastructure.
Another recurring theme in TherapeuticsMD’s news is its evaluation of strategic alternatives. In multiple press releases, the company states that it is exploring a variety of potential transactions, which may include an acquisition, merger, other business combination, sale of assets, or other strategic transactions involving the company. It also notes that there can be no assurance of any particular outcome and that no timetable has been set for this process.
Visitors to the TXMD news page can review this sequence of financial updates, commentary on the company’s royalty assets, and disclosures about its strategic review process. For investors and followers of TXMD stock, these news items provide insight into the company’s royalty revenue trends, expense profile, and the status of its exploration of possible strategic alternatives over time.
TherapeuticsMD (NASDAQ: TXMD) reported full year 2025 results with improved profitability and higher license revenue. Net loss from continuing operations narrowed to $0.7 million (loss per share $0.06), versus a $2.3 million loss in 2024.
License revenue rose to $3.0 million (a 71.6% increase). Total operating expenses declined to $7.4 million. The company held $7.5 million in cash and is actively evaluating strategic alternatives, with no timetable or assurance of a transaction.
TherapeuticsMD (NASDAQ: TXMD) reported third quarter 2025 results for the three months ended September 30, 2025. The company posted net income from continuing operations of $50,000 (approximately $0.00 per share) versus a net loss of $567,000 (about $0.05 per share) in Q3 2024. License revenue, primarily from the Mayne license agreement, was $784,000, up $237,000 year-over-year. Total operating expenses were $1.646 million, relatively flat versus prior year. The company reported $7.1 million in cash and cash equivalents as of September 30, 2025. Management said it is continuing to evaluate strategic alternatives with no timetable or assurance of a transaction.
TherapeuticsMD (NASDAQ: TXMD) reported positive Q2 2025 financial results, marking a significant turnaround with net income of $545,000 ($0.05 per share) compared to a net loss of $(1.05) million in Q2 2024. License revenues, primarily from the Mayne License Agreement, increased to $1.0 million, up from $234,000 year-over-year.
Operating expenses decreased by 45.5% to $1.647 million, mainly due to an impairment charge recorded in Q2 2024. The company ended the quarter with $6.1 million in cash and is actively evaluating strategic alternatives, including potential mergers, acquisitions, or asset sales.
TherapeuticsMD (NASDAQ: TXMD) reported its Q1 2025 financial results, showing a reduced net loss from continuing operations of $(636) thousand ($(0.06) per share), compared to $(809) thousand ($(0.07) per share) in Q1 2024. License revenues increased 25.8% to $393 thousand, primarily from the Mayne License Agreement, up from $313 thousand in Q1 2024. Operating expenses decreased 13.1% to $1,264 thousand due to improved efficiencies as a royalty-based business.
The company maintains $5.7 million in cash and cash equivalents as of March 31, 2025. TherapeuticsMD is actively evaluating strategic alternatives, including potential acquisitions, mergers, business combinations, or asset sales, though no specific timeline or guaranteed outcome has been established.
TherapeuticsMD (NASDAQ: TXMD) has reported its full year 2024 financial results, showing improved performance with a reduced net loss from continuing operations of $(2.3) million, or $(0.20) per share, compared to $(7.7) million, or $(0.74) per share in 2023.
The company's license revenue, primarily from the Mayne License Agreement, increased by 35.3% to $1.8 million in 2024, up from $1.3 million in 2023. Operating expenses decreased by 33.6% to $6.5 million from $9.8 million in 2023, reflecting the company's transition from a commercial to a royalty-based business model.
As of December 31, 2024, TXMD maintained $5.1 million in cash and cash equivalents. The company is currently evaluating strategic alternatives, including potential acquisitions, mergers, business combinations, or asset sales.
TherapeuticsMD (NASDAQ: TXMD) reported its Q3 2024 financial results, showing a reduced net loss of $(567) thousand ($(0.05) per share) compared to $(1.4) million ($(0.13) per share) in Q3 2023. License revenue, mainly from the Mayne License Agreement, increased to $547 thousand from $(53) thousand in Q3 2023. Operating expenses decreased by 18.3% to $1.4 million. The company ended the quarter with $5.0 million in cash and cash equivalents. TherapeuticsMD is currently evaluating strategic alternatives, including potential mergers, acquisitions, or asset sales.
TherapeuticsMD (NASDAQ: TXMD) reported its Q2 2024 financial results. The company, which owns pharmaceutical royalty rights, saw a net loss from continuing operations of $1.05 million ($0.09 per share), an improvement from the $2.4 million loss in Q2 2023. License revenue decreased by 46.5% to $234,000, primarily due to changes in sales of licensed products. Total operating expenses decreased by 8.1% to $2.7 million, reflecting cost optimization efforts. The company's cash and cash equivalents stood at $5.2 million as of June 30, 2024. TherapeuticsMD is currently evaluating strategic alternatives, including potential acquisitions, mergers, or asset sales.
TherapeuticsMD, Inc. reported its First Quarter 2024 Financial Results, showing a net loss from continuing operations of $(0.8) million, or $(0.07) per share, compared to $(2.3) million in 2023. The company generated approximately $1.2 million in gross license royalties under the Mayne License Agreement, with total operating expenses decreasing by 52.8% to $1.5 million. Additionally, the company is exploring various strategic alternatives without a set timetable for completion.
Summary not available.
Summary not available.